Floatz logo

Ipilimumab

Acral Lentiginous Melanoma

Emory Universitymonoclonal_antibodyPhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

18 Active assets in the Acral Lentiginous Melanoma cohort.

Asset / SponsorPhaseRating
Pembrolizumab
Yonsei University
Phase 2BB
Nivolumab
Fred Hutchinson Cancer Center
Phase 2B
Nilotinib
Institute of Cancer Research, United Kingdom
Phase 2B
Rivoceranib
Peking University Cancer Hospital & Institute
Phase 3B
Imatinib
National Cancer Institute (NCI)
Phase 2B

View all 29 →

Same molecule, other indications

Ipilimumab is also rated in:

metastatic neoplasmDormant
BB
Indicative ·
71 / 100
View asset →
Clinical Stage IV Cutaneous Melanoma AJCC v8Dormant
BB
Indicative ·
69 / 100
View asset →
cutaneous melanomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →